ArticlePloS one2014

Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.

Seiichi Okabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.